HUP0203139A2 - Foszfodiészteráz VII-gátló imidazolszármazékok és alkalmazásuk gyógyszerként - Google Patents
Foszfodiészteráz VII-gátló imidazolszármazékok és alkalmazásuk gyógyszerkéntInfo
- Publication number
- HUP0203139A2 HUP0203139A2 HU0203139A HUP0203139A HUP0203139A2 HU P0203139 A2 HUP0203139 A2 HU P0203139A2 HU 0203139 A HU0203139 A HU 0203139A HU P0203139 A HUP0203139 A HU P0203139A HU P0203139 A2 HUP0203139 A2 HU P0203139A2
- Authority
- HU
- Hungary
- Prior art keywords
- group
- diseases
- imidazole derivatives
- hydrogen atom
- pharmaceuticals
- Prior art date
Links
- 239000003814 drug Substances 0.000 title abstract 2
- 150000002460 imidazoles Chemical class 0.000 title abstract 2
- 229940079865 intestinal antiinfectives imidazole derivative Drugs 0.000 title abstract 2
- 239000002606 phosphodiesterase VII inhibitor Substances 0.000 title 1
- -1 indan-5-yl Chemical group 0.000 abstract 5
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 abstract 1
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 206010006458 Bronchitis chronic Diseases 0.000 abstract 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 abstract 1
- 208000011231 Crohn disease Diseases 0.000 abstract 1
- 206010012438 Dermatitis atopic Diseases 0.000 abstract 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 abstract 1
- 208000007514 Herpes zoster Diseases 0.000 abstract 1
- 208000026139 Memory disease Diseases 0.000 abstract 1
- 206010027476 Metastases Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 abstract 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 abstract 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 201000008937 atopic dermatitis Diseases 0.000 abstract 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
- 229910052794 bromium Inorganic materials 0.000 abstract 1
- 206010006451 bronchitis Diseases 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 238000006243 chemical reaction Methods 0.000 abstract 1
- 229910052801 chlorine Inorganic materials 0.000 abstract 1
- 239000000460 chlorine Substances 0.000 abstract 1
- 208000007451 chronic bronchitis Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 229910052731 fluorine Inorganic materials 0.000 abstract 1
- 239000011737 fluorine Substances 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 229910052740 iodine Inorganic materials 0.000 abstract 1
- 230000009401 metastasis Effects 0.000 abstract 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 229910052717 sulfur Chemical group 0.000 abstract 1
- 239000011593 sulfur Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Transplantation (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
Abstract
A találmány az (I) általános képletű imidazolszármazékokra - ahol R1jelentése hidrogénatom; A csoport; benzil-, indan-5-il- , 1,2,3,4-tetrahidronaftalin-5-il-, dibenzotiofen-2-il-csoport; vagyszubsztituálatlan, vagy halogénatommal, A csoporttal, A-CO-NHcsoporttal, benziloxi-, alkoxi-, COOH vagy COOA csoporttal mono-, di-vagy triszubsztituált fenilcsoport; R2 jelentése hidrogénatom vagy Acsoport; X jelentése oxigén- vagy kénatom; Hal jelentése fluor-,klór-, bróm- vagy jódatom; A jelentése 1-6 szénatomos alkilcsoport -,valamint fiziológiai szempontból elfogadható sóikra és/vagyszolvátjaira vonatkozik. Ezek a vegyületek gátolják a foszfodiészterázVII enzimet, és így olyan betegségek megszüntetésére alkalmazhatókgyógyszerként, amelyek a PDE VII enzimmel kapcsolatosak. Ilyenmegbetegedések például: asztma, krónikus bronchitis, atopikusbőrgyulladás, övsömör, gyulladásos megbetegedések, autoimmunbetegségek sclerosis multiplex, Crohn-betegség, csontritkulás,transzplantátumok kivetési reakciói, daganatáttételek, memóriazavarokés az ateroszklerózis. Ó
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19950647A DE19950647A1 (de) | 1999-10-21 | 1999-10-21 | Imidazolderivate als Phosphodiesterase VII-Hemmer |
| PCT/EP2000/009926 WO2001029049A2 (de) | 1999-10-21 | 2000-10-10 | Imidazolderivate als phosphodiesterase vii-hemmer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HUP0203139A2 true HUP0203139A2 (hu) | 2003-01-28 |
| HUP0203139A3 HUP0203139A3 (en) | 2004-12-28 |
Family
ID=7926352
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0203139A HUP0203139A3 (en) | 1999-10-21 | 2000-10-10 | Imidazole derivatives as phosphodiesterase vii inhibitors and their use as pharmaceuticals |
Country Status (22)
| Country | Link |
|---|---|
| EP (1) | EP1222193B1 (hu) |
| JP (1) | JP2003512381A (hu) |
| KR (1) | KR20020060201A (hu) |
| CN (1) | CN1382146A (hu) |
| AR (1) | AR026198A1 (hu) |
| AT (1) | ATE247121T1 (hu) |
| AU (1) | AU780788B2 (hu) |
| BR (1) | BR0014922A (hu) |
| CA (1) | CA2388314C (hu) |
| CZ (1) | CZ293751B6 (hu) |
| DE (2) | DE19950647A1 (hu) |
| DK (1) | DK1222193T3 (hu) |
| ES (1) | ES2200957T3 (hu) |
| HU (1) | HUP0203139A3 (hu) |
| MX (1) | MXPA02003952A (hu) |
| NO (1) | NO20021846D0 (hu) |
| PL (1) | PL355020A1 (hu) |
| PT (1) | PT1222193E (hu) |
| RU (1) | RU2259199C2 (hu) |
| SK (1) | SK4922002A3 (hu) |
| WO (1) | WO2001029049A2 (hu) |
| ZA (1) | ZA200203995B (hu) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003053975A1 (fr) * | 2001-12-13 | 2003-07-03 | Daiichi Suntory Pharma Co., Ltd. | Derives de pyrazolopyrimidinone possedant une activite inhibitrice de pde7 |
| DE10163991A1 (de) * | 2001-12-24 | 2003-07-03 | Merck Patent Gmbh | Pyrrolo-pyrimidine |
| JP2006219373A (ja) | 2003-06-13 | 2006-08-24 | Daiichi Asubio Pharma Co Ltd | Ｐｄｅ７阻害作用を有するピリジニルピラゾロピリミジノン誘導体 |
| JP2006219374A (ja) | 2003-06-13 | 2006-08-24 | Daiichi Asubio Pharma Co Ltd | Ｐｄｅ７阻害作用を有するイミダゾトリアジノン誘導体 |
| EP2433943B1 (en) | 2004-07-01 | 2013-09-11 | Daiichi Sankyo Company, Limited | Intermediates for thienopyrazole derivatives having PDE7 inhibitory activity |
| US8637528B2 (en) | 2007-03-27 | 2014-01-28 | Omeros Corporation | Use of PDE7 inhibitors for the treatment of movement disorders |
| CN104758291B (zh) | 2007-03-27 | 2020-03-03 | 奥默罗斯公司 | 用于治疗运动障碍的pde7抑制剂的用途 |
| KR102385359B1 (ko) | 2010-11-08 | 2022-04-11 | 오메로스 코포레이션 | Pde7 억제제를 사용한 중독 및 충동-조절 장애의 치료 |
| US9220715B2 (en) | 2010-11-08 | 2015-12-29 | Omeros Corporation | Treatment of addiction and impulse-control disorders using PDE7 inhibitors |
| WO2024038090A1 (en) | 2022-08-18 | 2024-02-22 | Mitodicure Gmbh | Use of substituted benzoxazole and benzofuran compounds for the treatment and prevention of diseases associated with chronic fatigue, exhaustion and/or exertional intolerance |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4305954A (en) * | 1981-02-11 | 1981-12-15 | E. I. Du Pont De Nemours And Company | Antiinflammatory 3,4-dihydro(or 1,4-dihydro)-2-[(substituted)thio]-[1]benzopyrano[3,4-d]imidazoles and their corresponding sulfoxides and sulfones |
| JP2003526608A (ja) * | 1998-10-15 | 2003-09-09 | バイオイメージ エイ／エス | 再分布及び／又は標的化での干渉によって得られる特異的治療の介入 |
| WO2000068230A1 (en) * | 1999-05-05 | 2000-11-16 | Darwin Discovery Limited | 9-(1,2,3,4-tetrahydronaphthalen-1-yl)-1,9-dihydropurin-6-one derivatives as pde7 inhibitors |
-
1999
- 1999-10-21 DE DE19950647A patent/DE19950647A1/de not_active Withdrawn
-
2000
- 2000-10-10 CA CA002388314A patent/CA2388314C/en not_active Expired - Fee Related
- 2000-10-10 BR BR0014922-5A patent/BR0014922A/pt not_active IP Right Cessation
- 2000-10-10 SK SK492-2002A patent/SK4922002A3/sk unknown
- 2000-10-10 MX MXPA02003952A patent/MXPA02003952A/es unknown
- 2000-10-10 AU AU11356/01A patent/AU780788B2/en not_active Ceased
- 2000-10-10 JP JP2001531847A patent/JP2003512381A/ja active Pending
- 2000-10-10 CN CN00814402A patent/CN1382146A/zh active Pending
- 2000-10-10 PT PT00972714T patent/PT1222193E/pt unknown
- 2000-10-10 PL PL00355020A patent/PL355020A1/xx unknown
- 2000-10-10 HU HU0203139A patent/HUP0203139A3/hu unknown
- 2000-10-10 RU RU2002111413/15A patent/RU2259199C2/ru not_active IP Right Cessation
- 2000-10-10 AT AT00972714T patent/ATE247121T1/de not_active IP Right Cessation
- 2000-10-10 DE DE50003309T patent/DE50003309D1/de not_active Expired - Lifetime
- 2000-10-10 DK DK00972714T patent/DK1222193T3/da active
- 2000-10-10 CZ CZ20021251A patent/CZ293751B6/cs not_active IP Right Cessation
- 2000-10-10 WO PCT/EP2000/009926 patent/WO2001029049A2/de active IP Right Grant
- 2000-10-10 ES ES00972714T patent/ES2200957T3/es not_active Expired - Lifetime
- 2000-10-10 EP EP00972714A patent/EP1222193B1/de not_active Expired - Lifetime
- 2000-10-10 KR KR1020027004903A patent/KR20020060201A/ko not_active Application Discontinuation
- 2000-10-20 AR ARP000105542A patent/AR026198A1/es unknown
-
2002
- 2002-04-19 NO NO20021846A patent/NO20021846D0/no not_active Application Discontinuation
- 2002-05-20 ZA ZA200203995A patent/ZA200203995B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2001029049A2 (de) | 2001-04-26 |
| DE50003309D1 (de) | 2003-09-18 |
| PL355020A1 (en) | 2004-03-22 |
| ATE247121T1 (de) | 2003-08-15 |
| RU2259199C2 (ru) | 2005-08-27 |
| PT1222193E (pt) | 2003-12-31 |
| AR026198A1 (es) | 2003-01-29 |
| CN1382146A (zh) | 2002-11-27 |
| AU780788B2 (en) | 2005-04-14 |
| EP1222193B1 (de) | 2003-08-13 |
| NO20021846L (no) | 2002-04-19 |
| KR20020060201A (ko) | 2002-07-16 |
| HUP0203139A3 (en) | 2004-12-28 |
| DK1222193T3 (da) | 2003-12-01 |
| CA2388314C (en) | 2009-06-16 |
| MXPA02003952A (es) | 2004-09-06 |
| ES2200957T3 (es) | 2004-03-16 |
| ZA200203995B (en) | 2003-10-29 |
| NO20021846D0 (no) | 2002-04-19 |
| CZ20021251A3 (cs) | 2002-07-17 |
| SK4922002A3 (en) | 2002-09-10 |
| CA2388314A1 (en) | 2001-04-26 |
| DE19950647A1 (de) | 2001-04-26 |
| BR0014922A (pt) | 2002-06-11 |
| EP1222193A2 (de) | 2002-07-17 |
| JP2003512381A (ja) | 2003-04-02 |
| AU1135601A (en) | 2001-04-30 |
| CZ293751B6 (cs) | 2004-07-14 |
| WO2001029049A3 (de) | 2001-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA200700711A1 (ru) | Производные бензимидазолуксусной кислоты, проявляющие антагонизм в отношении рецептора crth2, и их применение | |
| HUP0401097A2 (hu) | Karbociklusos hidrazinovegyületek, mint a réztartalmú aminoxidázok inhibitorai, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
| HUP0300909A2 (hu) | NHE-3 inhibitor hatású 2-guanidino-4-aril-kinazolin-származékok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
| HUP0203139A2 (hu) | Foszfodiészteráz VII-gátló imidazolszármazékok és alkalmazásuk gyógyszerként | |
| TNSN07050A1 (fr) | Derives de triazolopyridinylsulfanyle servant d'inhibiteurs de kinase map p38 | |
| MXPA05011581A (es) | Derivados de acido 3-(1-naftil)-2-cianopropanoico como ligandos receptores de estrogenos. | |
| DE69912581D1 (de) | Biarylessigsäure-derivate und ihre verwendung als cox-2 inhibitoren | |
| BR9808998A (pt) | Imidazóis substituìdos úteis no tratamento de doenças inflamatórias | |
| FI932229A (fi) | Azabicykliska bryggderivat | |
| HUP9802422A2 (hu) | Szubsztituált izokinolin-3-karbonsavamid-származékok, eljárás előállításukra és ezeket a vegyületeket tartalmazó gyógyszerkészítmények | |
| HUP0203376A2 (hu) | Ciklooxigenáz-2 inhibitor hatású 5-aril-1h-1,2,4-triazol-származékok és ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
| HUP0203422A2 (hu) | Foszfodiészteráz VII inhibitor hatású imidazolszármazékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
| GEP19970786B (en) | Method of n-/2-/4-fluorphenyl/-1-methyl-ethyl-n-methyl-n-propinylamine production | |
| HUP9802132A2 (hu) | Bifenil-szulfonil-ciánamidok, alkalmazásuk és az ezeket tartalmazó gyógyszerkészítmények | |
| MY133370A (en) | Carbamate compounds for use in preventing or treating bipolar disorders | |
| CA2099867A1 (en) | 2-substituted-4,6-di-tertiary-butyl-5-hydroxy-1,3-pyrimidines useful as antiinflammatory agents | |
| HUP0001093A2 (hu) | 5-HT2A-antagonista oxazolidinon-származékok, az ezeket tartalmazó gyógyszerkészítmények és eljárás előállításukra | |
| HUP9901212A2 (hu) | N,N-dialkil-N-[2-(3-alkoxi-fenoxi)-etil]-amin-származékok, az ezeket tartalmazó gyógyszerkészítmények és helyi érzéstelenítőkként való alkalmazásuk | |
| HUP0300562A2 (hu) | [(Hidroxi-fenil)-piperazinil-metil]-benzamid-származékok fájdalom kezelésére, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
| HUP0003155A2 (hu) | Eljárás COX-2 inhibitorként alkalmazható 2-aril-3-aril-5-halogénpiridin-származékok előállítására | |
| MY127317A (en) | Carbamate compounds for use in preventing or treating neuropathic pain and cluster and migraine headache-associated pain | |
| HUP0402033A2 (hu) | 2-Amino-4-piridil-metil-tiazolin-származékok alkalmazása az indukálható NO-szintetáz inhibitoraként, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
| HUP9904086A2 (hu) | 4-es Helyzetben szubsztituált piperidinszármazékok és a vegyületeket tartalmazó gyógyszerkészítmények | |
| HUP0002083A2 (hu) | Sok gyógyszerrel szemben rezisztens inhibitor akridinszármazék szintézise | |
| HUP9900679A2 (hu) | Simaizom sejtburjánzást gátló benzimidazolszármazékok, eljárás előállításukra és ezeket tartalmazó gyógyszerkészítmények |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD9A | Lapse of provisional protection due to non-payment of fees |